Amussen Hunsaker Associates LLC cut its position in shares of Healthequity Inc (NASDAQ:HQY) by 0.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 87,445 shares of the company’s stock after selling 181 shares during the quarter. Healthequity makes up about 4.4% of Amussen Hunsaker Associates LLC’s holdings, making the stock its 8th biggest position. Amussen Hunsaker Associates LLC owned approximately 0.14% of Healthequity worth $5,216,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Morgan Stanley raised its position in Healthequity by 15.5% in the third quarter. Morgan Stanley now owns 4,001,425 shares of the company’s stock worth $377,775,000 after acquiring an additional 536,366 shares during the period. Clearbridge Investments LLC raised its position in Healthequity by 976,643.6% in the third quarter. Clearbridge Investments LLC now owns 380,930 shares of the company’s stock worth $35,964,000 after acquiring an additional 380,891 shares during the period. Massachusetts Financial Services Co. MA bought a new stake in Healthequity in the fourth quarter worth about $15,455,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in Healthequity in the third quarter worth about $19,021,000. Finally, Pictet Asset Management Ltd. bought a new stake in Healthequity in the third quarter worth about $18,882,000. Institutional investors and hedge funds own 96.26% of the company’s stock.

Several analysts have commented on the stock. Cantor Fitzgerald lifted their price objective on shares of Healthequity from $80.00 to $83.00 and gave the stock an “overweight” rating in a research report on Thursday, February 7th. KeyCorp lifted their price objective on shares of Healthequity from $74.00 to $90.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 19th. BidaskClub raised shares of Healthequity from a “hold” rating to a “buy” rating in a research report on Saturday, December 1st. Citigroup set a $102.00 price objective on shares of Healthequity and gave the stock a “buy” rating in a research report on Tuesday, January 8th. Finally, Wells Fargo & Co lowered their price objective on shares of Healthequity from $100.00 to $90.00 and set an “outperform” rating on the stock in a research report on Friday, December 7th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Healthequity currently has an average rating of “Buy” and a consensus target price of $86.85.

In related news, VP Darcy G. Mott sold 4,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 22nd. The shares were sold at an average price of $60.81, for a total transaction of $243,240.00. Following the completion of the transaction, the vice president now owns 79,200 shares of the company’s stock, valued at $4,816,152. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Delano Ladd sold 6,875 shares of the business’s stock in a transaction that occurred on Wednesday, February 20th. The shares were sold at an average price of $78.00, for a total transaction of $536,250.00. Following the transaction, the executive vice president now directly owns 14,340 shares of the company’s stock, valued at approximately $1,118,520. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 18,875 shares of company stock valued at $1,429,370. 4.00% of the stock is owned by corporate insiders.

NASDAQ HQY opened at $73.57 on Tuesday. Healthequity Inc has a 12-month low of $50.29 and a 12-month high of $101.58. The company has a market capitalization of $4.60 billion, a PE ratio of 77.44, a price-to-earnings-growth ratio of 2.53 and a beta of 1.72.

Healthequity (NASDAQ:HQY) last posted its quarterly earnings results on Monday, March 18th. The company reported $0.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.06. Healthequity had a net margin of 25.73% and a return on equity of 13.59%. The company had revenue of $75.78 million for the quarter, compared to analyst estimates of $74.28 million. During the same quarter in the previous year, the firm posted $0.09 earnings per share. The company’s quarterly revenue was up 25.4% compared to the same quarter last year. On average, sell-side analysts expect that Healthequity Inc will post 0.94 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Amussen Hunsaker Associates LLC Sells 181 Shares of Healthequity Inc (HQY)” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.watchlistnews.com/amussen-hunsaker-associates-llc-sells-181-shares-of-healthequity-inc-hqy/2917925.html.

Healthequity Profile

HealthEquity, Inc provides various solutions for managing health care accounts, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators in the United States. The company offers healthcare saving and spending platform, a cloud-based platform for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

See Also: What are the Benefits of Index Funds?

Want to see what other hedge funds are holding HQY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Healthequity Inc (NASDAQ:HQY).

Institutional Ownership by Quarter for Healthequity (NASDAQ:HQY)

Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.